Skip to main content
SKINBIOTHERAPEUTICS PLC logo

SKINBIOTHERAPEUTICS PLC — Investor Relations & Filings

Ticker · SBTX ISIN · GB00BF33H870 LEI · 213800YMQOCB23FX6I06 IL Manufacturing
Open in API
Filings indexed 315 across all filing types
Latest filing 2023-12-06 Report Publication Anno…
Country GB United Kingdom
Listing IL SBTX

About SKINBIOTHERAPEUTICS PLC

https://www.skinbiotherapeutics.com/

SkinBioTherapeutics PLC is a life science company focused on advancing skin health by harnessing the human microbiome. Its proprietary SkinBiotix® platform technology utilizes probiotic lysates to protect, manage, and restore skin. The company develops and commercializes products across several healthcare sectors, including cosmetics, food supplements, medical devices, and pharmaceuticals. Key offerings include AxisBiotix, a probiotic food supplement designed to address psoriasis symptoms, and the Dermatonics line of specialized foot care products. Through its acquisition of Bio-Tech Solutions, the company also provides formulation, manufacturing, and packaging services for healthcare, personal care, and hygiene products.

Recent filings

Filing Released Lang Actions
Notice of AGM and posting of Annual Report
Report Publication Announcement Classification · 100% confidence The document explicitly states: "Posting of Annual Report and AGM Notice". It confirms that the "Notice of Annual General Meeting ("AGM"), form of proxy and Annual Report and Accounts for the year ended 30 June 2023 have been posted to shareholders." Since the document is a short announcement (3269 chars) whose primary purpose is to inform shareholders that the Annual Report and AGM Notice have been published and are available elsewhere (website/posted), it fits the definition of a Report Publication Announcement (RPA) based on the 'MENU VS MEAL' rule. Although it mentions the AGM Notice (AGM-R) and Annual Report (10-K), the filing itself is the announcement of their release.
2023-12-06 English
Final Results
Earnings Release Classification · 95% confidence The document is titled 'Full year results' and provides a comprehensive overview of the company's financial performance, operational highlights, and management commentary for the 12-month period ending 30 June 2023. It contains detailed financial data, including revenue, operating loss, and cash position, as well as a 'Chairman and Chief Executive's Statement' and 'Financial review'. While it is distributed via an RNS (Regulatory News Service) platform, it constitutes the actual release of the annual financial results rather than a mere announcement of a report's availability. Therefore, it is classified as an Earnings Release (ER) as it serves as the initial announcement of the period's financial results. FY 2023
2023-11-30 English
AxisBiotix-Ps™ to launch on Amazon UK
Regulatory Filings Classification · 100% confidence The document is identified by the header "RNS Number : 1351V" and concludes with information about RNS, the news service of the London Stock Exchange, which acts as a Primary Information Provider. The content itself is a short announcement regarding the launch of a product (AxisBiotix-Ps™) on Amazon UK and future expansion plans. This is a general regulatory announcement that does not fit the specific criteria for financial reports (10-K, IR, ER), management changes (MANG), or shareholder actions (DIV, DVA). Given its nature as a general, time-sensitive update distributed via the official exchange news service (RNS), the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such announcements.
2023-11-30 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number : 5310U' on '24 November 2023'. It details changes in voting rights percentages (crossing thresholds from 15.7% to 13.52%) held by a specific entity (Optibiotix Health PLC) in SkinBioTherapeutics PLC. This type of filing, which reports changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the classification over the general RNS fallback.
2023-11-24 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly identified as an 'RNS Number' filing from 'SkinBioTherapeutics PLC' dated '23 November 2023'. The form title is 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the content is specific enough to warrant the MRQ classification over the general RNS fallback.
2023-11-23 English
Update regarding Nominated Adviser and Broker
Regulatory Filings Classification · 98% confidence The document is very short (3291 characters) and is clearly identified as originating from 'RNS Number : 2069U' and distributed by 'RNS, the news service of the London Stock Exchange'. The content announces a change in the company's Nominated Adviser and Broker due to a merger within the advisory group. This type of announcement, which is a formal regulatory update distributed via the RNS system but does not fit into specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), is best classified as a general Regulatory Filing or announcement. Since it is a standard, non-specific regulatory news service release, the most appropriate fallback category is RNS.
2023-11-22 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.